Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO NASDAQ:CNSP NASDAQ:RDHL NASDAQ:VCNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.62+2.5%$1.68$1.32▼$381.10$5.33M5.872.53 million shs851,346 shsCNSPCNS Pharmaceuticals$9.15-0.5%$7.74$4.93▼$221.94$5.22M2.6879,519 shs12,187 shsRDHLRedhill Biopharma$1.73+15.3%$1.59$1.06▼$9.00$5.76M4.57670,242 shs24.91 million shsVCNXVaccinex$0.97+104.1%$0.59$0.25▼$1.40$2.52M1.12,813 shs1,951 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%+0.64%-10.23%-48.20%-99.97%CNSPCNS Pharmaceuticals0.00%-5.15%+15.29%+2.89%-87.43%RDHLRedhill Biopharma0.00%-11.76%-11.24%-36.17%-82.93%VCNXVaccinex0.00%-6.86%-32.13%-53.34%-81.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.62+2.5%$1.68$1.32▼$381.10$5.33M5.872.53 million shs851,346 shsCNSPCNS Pharmaceuticals$9.15-0.5%$7.74$4.93▼$221.94$5.22M2.6879,519 shs12,187 shsRDHLRedhill Biopharma$1.73+15.3%$1.59$1.06▼$9.00$5.76M4.57670,242 shs24.91 million shsVCNXVaccinex$0.97+104.1%$0.59$0.25▼$1.40$2.52M1.12,813 shs1,951 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%+0.64%-10.23%-48.20%-99.97%CNSPCNS Pharmaceuticals0.00%-5.15%+15.29%+2.89%-87.43%RDHLRedhill Biopharma0.00%-11.76%-11.24%-36.17%-82.93%VCNXVaccinex0.00%-6.86%-32.13%-53.34%-81.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 2.33HoldN/AN/ACNSPCNS Pharmaceuticals 2.33Hold$20.00118.58% UpsideRDHLRedhill Biopharma 1.00SellN/AN/AVCNXVaccinex 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VCNX, CNSP, APVO, and RDHL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025APVOAptevo TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)10/8/2025CNSPCNS PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025RDHLRedhill BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025APVOAptevo TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)9/27/2025CNSPCNS PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RDHLRedhill BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/18/2025APVOAptevo TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/16/2025APVOAptevo TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/12/2025CNSPCNS PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$20.00(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M1.71N/AN/A$65.21 per share0.02CNSPCNS PharmaceuticalsN/AN/AN/AN/A$64.50 per shareN/ARDHLRedhill Biopharma$8.04M0.72N/AN/A($3.66) per share-0.47VCNXVaccinex$388K6.50N/AN/A($2.59) per share-0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-675.52%-175.68%11/6/2025 (Estimated)CNSPCNS Pharmaceuticals-$14.86M-$3,748.50N/A∞N/AN/A-183.89%-139.37%11/13/2025 (Estimated)RDHLRedhill Biopharma-$8.27MN/A0.00∞N/AN/AN/AN/AN/AVCNXVaccinex-$20.25M-$48.27N/A∞N/AN/AN/A-383.58%11/12/2025 (Estimated)Latest VCNX, CNSP, APVO, and RDHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025N/AAPVOAptevo Therapeutics-$2.09N/AN/AN/AN/AN/A8/14/2025Q2 2025CNSPCNS Pharmaceuticals-$9.60-$6.42+$3.18-$6.42N/AN/A8/11/2025Q2 2025APVOAptevo Therapeutics-$83.20-$8.40+$74.80-$8.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A2.272.27CNSPCNS PharmaceuticalsN/A10.2210.22RDHLRedhill BiopharmaN/A0.560.42VCNXVaccinexN/A0.770.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%CNSPCNS Pharmaceuticals14.02%RDHLRedhill Biopharma7.20%VCNXVaccinex50.11%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.12%CNSPCNS Pharmaceuticals0.07%RDHLRedhill Biopharma6.81%VCNXVaccinex51.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics503.29 million3.28 millionNot OptionableCNSPCNS Pharmaceuticals5570,000575,000Not OptionableRDHLRedhill Biopharma2103.33 million3.10 millionNo DataVCNXVaccinex402.60 million1.26 millionNo DataVCNX, CNSP, APVO, and RDHL HeadlinesRecent News About These CompaniesVaccinex presents promising cancer treatment data at ASCOMay 29, 2025 | uk.investing.comVaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025May 29, 2025 | nasdaq.comVaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual MeetingMay 27, 2025 | globenewswire.comAbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug TargetsMay 13, 2025 | finanznachrichten.deAbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug TargetsMay 13, 2025 | finance.yahoo.comVaccinex to report new clinical data on pepinemab in enhancing immunotherapyApril 22, 2025 | markets.businessinsider.comVaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025April 21, 2025 | quiverquant.comQVaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)April 21, 2025 | globenewswire.comVaccinex director resigns, no disagreement citedMarch 21, 2025 | investing.comVaccinex plans Nasdaq exit as Alzheimer market pressure growsMarch 10, 2025 | finance.yahoo.comVaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock MarketMarch 8, 2025 | finanznachrichten.deVaccinex to delist common stock from NasdaqMarch 7, 2025 | markets.businessinsider.comVaccinex Plans to Delist its Common Stock from The Nasdaq Stock MarketMarch 7, 2025 | globenewswire.comPepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comPVaccinex receives delisting notification from NasdaqDecember 17, 2024 | markets.businessinsider.comVaccinex Announces Receipt of Delisting Notification from NasdaqDecember 17, 2024 | markets.businessinsider.comVaccinex Shares Tumble 63% On Nasdaq DelistingDecember 17, 2024 | marketwatch.comVaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%December 17, 2024 | finance.yahoo.comVaccinex Faces Nasdaq Delisting: What's Going On With The Stock?December 17, 2024 | benzinga.comVaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing StandardsDecember 17, 2024 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCNX, CNSP, APVO, and RDHL Company DescriptionsAptevo Therapeutics NASDAQ:APVO$1.62 +0.04 (+2.53%) Closing price 04:00 PM EasternExtended Trading$1.62 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.CNS Pharmaceuticals NASDAQ:CNSP$9.15 -0.05 (-0.54%) Closing price 03:59 PM EasternExtended Trading$8.60 -0.55 (-6.00%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Redhill Biopharma NASDAQ:RDHL$1.73 +0.23 (+15.33%) Closing price 04:00 PM EasternExtended Trading$1.66 -0.06 (-3.76%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Vaccinex NASDAQ:VCNX$0.97 +0.49 (+104.08%) As of 12:51 PM EasternVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
